Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.
作者： David R Spigel , Martin J Edelman , Kenneth O'Byrne , Luis Paz-Ares , David S Shames
DOI: 10.1200/JCO.2014.32.15_SUPPL.8000
关键词: Erlotinib 、 Stage iiib 、 Oncology 、 Surgery 、 Placebo 、 Previously treated 、 Onartuzumab 、 Medicine 、 Internal medicine 、 Cancer research
摘要: 8000 Background: A placebo-controlled, phase II trial of erlotinib + onartuzumab, a humanized monovalent antibody to the MET receptor, demonstrated benefit in progression-free survival (PFS) when...
sci-hub.st 参考文章(0)